Gene expression in human keratinocytes from psoriatic skin (directly into the lesion or in area without lesion) or healthy person (control) used for human tissue-engineered skin substitutes and co-cultured with T-lymphocyte. Gene expression in human keratinocytes from psoriatic skin (directly into the lesion or in area without lesion) or healthy person (control) used for human tissue-engineered skin substitutes and co-cultured with T-lymphocyte

The objective of this study was to find deregulated genes between healthy and psoriatic T cell-enriched tissue-engineered models to develop a new therapeutic pathway in psoriasis treatment. In this study, we used a tissue-engineered, two-layers (dermis and epidermis) human skin substitute enriched in T cells as a biomaterial to study both the cellular and molecular mechanisms involved in psoriasis’ pathogenesis. Overall design: 3 human healthy keratinocytes population (at passage 3) from 3 healthy donors (18-, 46- and 49-years old), 4 human psoriatic keratinocytes population (at passage 3) from directly into the lesion of 4 psoriatic patients (36-, 46-, 49- and 64- years old) and 3 human psoriatic keratinocytes population (at passage 3) from area without lesion of three psoriatic patients (46-, 49- and 64- years old) co-cultured or not with T-lymphocyte from human tissue-engineered skin substitutes are analyzed by gene profiling.